A recent review of existing research suggests that advanced clear cell renal cell carcinoma (ccRCC) may be classified into four immune subtypes, or ecotypes. These categories could help explain why some patients respond well to immune checkpoint inhibitors while others do not. The proposed ecotypes include T-cell-inflamed but dysfunctional tumors, myeloid-dominant suppressive tumors, angiogenesis- and hypoxia-skewed tumors, and immune-excluded tumors.
The review highlights that current biomarkers such as PD-L1, tumor mutational burden, and inflammatory gene signatures are not enough to predict treatment response or guide routine therapy choices. The authors argue that a more detailed immune-ecological perspective may lead to better patient stratification and more personalized immunotherapy strategies.
It is important to note that this is a review of existing literature, not a primary clinical trial. The proposed ecotypes are not yet a validated clinical tool. More research is needed to confirm whether these subtypes can reliably guide treatment decisions.
For now, patients with advanced ccRCC should continue to discuss treatment options with their oncologist based on current evidence and guidelines. This review offers a promising framework for future studies but does not change current clinical practice.
